Report Description of the APAC OTC Gastrointestinal Drugs Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for APAC OTC Gastrointestinal Drugs Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the APAC OTC Gastrointestinal Drugs Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

APAC OTC Gastrointestinal Drugs Market Analysis Executive Summary

Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder, and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation, and many more. The diseases of gastrointestinal have become common in the people across world. Gastrointestinal diseases are caused by various reasons such as acid reflux, heartburn, indigestion, nausea and vomiting, peptic ulcer disease, abdominal pain syndrome, biliary tract disorders, gallbladder disorders, and gallstone pancreatitis.

Market Size and Key Findings

The APAC OTC Gastrointestinal Drugs Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 6.1% during the forecast period.



Market Dynamics

Market Growth Drivers Analysis

Gastrointestinal diseases has gained a tremendous attention over the last few years. Owing to increasing prevalence of different gastrointestinal diseases and disorders, encouraged many companies for initiating the research in the development of innovative and advanced drugs. Increasing prevalence of GI diseases, rising geriatric population, and increasing investment in research & development drives the growth of the Asia-Pacific gastrointestinal drugs market. Additionally, changing lifestyle and increasing awareness about the availability of the treatment fuel the Asia-Pacific gastrointestinal drugs market growth.

Market Restraints

The presence of misbranded & spurious drugs, and unavailability of lifelong cure may hinder the Asia-Pacific gastrointestinal drugs market growth over the review period.

COVID-19 impact on APAC OTC Gastrointestinal Drugs Market

Most industries across the world have been negatively impacted over the last few months. This can be attributed to significant disruptions experienced by their respective manufacturing and supply-chain operations as a result of various precautionary lockdowns, as well as other restrictions that were enforced by governing authorities across the globe. The same applies to the global Gastrointestinal Drugs market.

Competitive Landscape

Key Players

Takeda pharmaceutical, Valeant Pharmaceuticals International, Inc., Janssen Biotech, Inc., Bayer AG, Sanofi, AstraZeneca, Allergan Plc, GlaxoSmithKline, Abbott Laboratories, Boehringer Ingelheim GmbH and Allergan Plc.

Products in Pipeline

• In March 2016, Allergan enters into licensing agreement with AstraZeneca to obtain worldwide rights to MEDI2070 inflammatory disorder development program. Which will expands Allergans Innovative Gastroenterology Pipeline into Inflammatory Bowel Disease.

Notable Recent Deals

In June 2017, Abbott accepted shareholders amended merger from Alere. Merger will increase the revenue in Abbotts pharmaceuticals segment.

In October 2016, Allergan has acquired GI Disease Subsidiary of Rhythm Holding Company, acquisition will expand the innovative gastroenterology segment of Allergen indirectly increasing revenue.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The government of Asian countries have been educating the people about the various diseases and their treatment availability. Relief International, with funding from the European Union, is working with Bangladesh citizens to implement One Health Asia, a program designed to prevent zoonotic diseases through training and education. Many organizations and companies are conducting surveys and programs to educate the peoples about the diseases and treatment.